ClinicalTrials.Veeva

Menu

Permanent Supportive Housing Overdose Prevention-2 Study (POP-2)

NYU Langone Health logo

NYU Langone Health

Status

Begins enrollment in a year or more

Conditions

Substance Use
Overdose

Treatments

Behavioral: TA Intervention

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT07214519
UG3DA063084 (U.S. NIH Grant/Contract)
(Pending) POP-2

Details and patient eligibility

About

This community-partnered study examines a technical assistance intervention designed to help permanent supportive housing agencies implement evidence-based practices to prevent tenant overdose and improve tenant health.

Full description

Homelessness and housing instability are strongly linked with overdose risk. Permanent supportive housing (PSH) -subsidized housing paired with supportive services-is a key strategy to end homelessness yet supportive housing tenants face high overdose risk due to a confluence of factors. This multi-sector, community-partnered, stepped wedge randomized controlled trial evaluates the impact of a technical assistance intervention designed to support supportive housing agencies in sustainably implementing evidence-based practices to reduce tenant overdose and improve tenant health more broadly. The technical assistance intervention will be delivered to supportive housing agencies in New Jersey and New York who are enrolled in the trial. Outcomes include PSH agency implementation of overdose prevention practices and downstream tenant overdose, substance use, and other health-related outcomes. Outcomes will be assessed using surveys, administrative data, and agency records.

Enrollment

2,940 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

We will be enrolling supportive housing agencies from NY and NJ to participate in this study. Trial enrollment and intervention delivery will occur at the level of the agency. There are anticipated to be 24 supportive housing agencies total that will be enrolled in the study; approximately 6 agencies will be randomly assigned to each of the four intervention waves in the stepped wedge randomized controlled trial.

Inclusion Criteria:

Supportive Housing Agencies/Individuals who Work at Supportive Housing Agencies:

  • Serve at least 40 tenants in New York and/or New Jersey
  • Have a significant concern for overdose (as demonstrated by past year tenant overdose)
  • Be willing to complete all activities required for participation in the trial

Tenants who Live in Supportive Housing Agencies:

  • Must live in an enrolled Supportive Housing Agency
  • Must be 18 years and older

Exclusion Criteria:

  • See inclusion criteria.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

2,940 participants in 4 patient groups

Wave 1: Control, Intervention, Sustainment
Experimental group
Description:
Participants at agencies assigned to wave 1 will receive the control condition from months 1-6; intervention for months 6-12; and sustainment from months 12-45.
Treatment:
Behavioral: TA Intervention
Wave 2: Control, Intervention, Sustainment
Experimental group
Description:
Participants at agencies assigned to wave 2 will receive the control condition from months 1-13; intervention for months 13-19; and sustainment from months 19-45.
Treatment:
Behavioral: TA Intervention
Wave 3: Control, Intervention, Sustainment
Experimental group
Description:
Participants at agencies assigned to wave 3 will receive the control condition from months 1-20; intervention for months 20-26; and sustainment from months 26-45.
Treatment:
Behavioral: TA Intervention
Wave 4: Control, Intervention, Sustainment
Experimental group
Description:
Participants at agencies assigned to wave 4 will receive the control condition from months 1-27; intervention for months 27-33; and sustainment from months 33-45.
Treatment:
Behavioral: TA Intervention

Trial contacts and locations

1

Loading...

Central trial contact

Kelly Doran, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems